Dr. Alan Tan, Dr. Brad McGregor, and Dr. Amanda Nizam discuss how management of muscle-invasive bladder cancer is rapidly evolving, with perioperative EV pembrolizumab and chemoimmunotherapy now offering significant improvements in survival. They emphasize that this disease should be treated as systemic from the outset, making early multidisciplinary evaluation and medical oncology involvement essential to improve cure rates. While bladder preservation strategies are gaining interest, patient selection remains critical, with biomarkers like ctDNA expected to refine decisions around adjuvant therapy and long-term management.
Contributors:
Dr. Alan Tan is a medical oncologist practicing at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.
Dr. Amanda Nizam is a genitourinary medical oncologist practicing at Clevelant Clinic in Cleveland, Ohio.
Dr. Brad McGregor is a medical oncologist and the Director of Clinical Research at the Lank Center of Genitourinary Oncology in Boston, Massachusetts.